Drug Search Results
More Filters [+]

INV-322

Alternative Names: INV-322, INV322, INV 322
Latest Update: 2022-09-20
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: CTLA4 Inhibitor,CD25 Antagonist

Novel Mechanism: Yes

Modality: N/A

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Invenra
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for INV-322

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 0: Oncology Solid Tumor Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events